Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone plus apalutamide for metastatic hormone-sensitive prostate cancer
ChiCTR2200060388Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apalutamide and prednisone in prostate cancer (PCa) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Incidence of rash. Started Jun 2021; status: recruiting.
02
Drugs
apalutamideprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2200060388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060388.